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Abstract
No one likes to feel like they have been manipulated, but in the case of cytomegalovirus (CMV)
immune manipulation, we do not really have much choice. Whether you call it CMV immune
modulation, manipulation, or evasion, the bottom line is that CMV alters the immune response in
such a way to allow the establishment of latency with lifelong shedding. With millions of years of
coevolution within their hosts, CMVs, like other herpesviruses, encode numerous proteins that can
broadly influence the magnitude and quality of both innate and adaptive immune responses. These
viral proteins include both homologues of host proteins, such as MHC class I or chemokine
homologues, and proteins with little similarity to any other known proteins, such as the chemokine
binding protein. Although a strong immune response is launched against CMV, these virally
encoded proteins can interfere with the host's ability to efficiently recognize and clear virus, while
others induce or alter specific immune responses to benefit viral replication or spread within the
host. Modulation of host immunity allows survival of both the virus and the host. One way of
describing it would be a kind of "mutually assured survival" (as opposed to MAD, Mutually Assured
Destruction). Evaluation of this relationship provides important insights into the life cycle of CMV
as well as a greater understanding of the complexity of the immune response to pathogens in
general.
Introduction
After an initial primary infection herpesviruses establish
latency for the life of the host with periodic and spontane-
ous reactivation. The coevolution of herpesviruses along
with their host allowed these viruses to evolve mecha-
nisms to modulate the host immune response. While
some virally encoded proteins facilitate immune evasion,
interfering with the host's ability to efficiently recognize
and clear virus, others induce or alter specific immune
responses to benefit the viral life cycle. Among the herpes-
viruses, cytomegaloviruses (CMVs) encode the greatest
number of genes committed to altering both innate and
adaptive immune responses (Additional files 1 and 2).
Innate Immune Responses
Complement Cascade
The complement system is composed of a number of
plasma proteins that induce inflammatory mediators,
opsonization of pathogens, and direct lysis of pathogens
and infected cells. The binding of complement proteins to
antibody-antigen complexes activates the classical com-
plement pathway, bridging innate and humoral immune
responses. The binding of complement proteins directly
to the surface of pathogens or infected cells initiates the
alternative pathway. Both pathways lead to a common
activation of the C3 convertase and subsequent elicitation
of chemoattractants (e.g. C5a), opsonizing factors (e.g.
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C3b) and the membrane attack complex. Antibody-medi-
ated complement lysis is an important mechanism for
elimination of virus-infected cells. Therefore, a number of
herpesviruses encode complement regulatory proteins.
Herpes simplex virus 1 (HSV-1) and Epstein Barr virus
(EBV) both have homologues of regulators of comple-
ment activation (RCA) proteins, such as CD46 and CD55
[1]. Complement control proteins including CD46,
CD55, and CD59 regulate and also inhibit various stages
within the complement cascade [2]. While no CMV
encoded RCA homologues have been identified, CMVs
have evolved mechanisms for limiting complement activ-
ity. HCMV infected fibroblasts are resistant to comple-
ment lysis when treated with CMV-specific antibodies,
which would be expected to induce the classical comple-
ment pathway [3]. Human CMV (HCMV) incorporates
cellular CD55 and CD59 into its virion. The importance
of these complement inhibitory proteins was demon-
strated when antibodies against CD55 decreased HCMV
replication in fibroblasts following incubation with com-
plement components [4]. The decrease in viral titers in the
presence of these antibodies showed that inhibition of
complement activation (i.e. interfering with inhibitory
CD55) is important for HCMV replication. HCMV also
upregulates the expression of CD46 and CD55 on the sur-
face of infected cells, which decreases the accumulation of
C3 convertases. This in turn, protects the cells from com-
plement mediated lysis [5]. Although the mechanisms dif-
fer from other herpesviruses, HCMV is able to inactivate
the complement cascade, increasing virus replication/sur-
vival.
Mouse CMV (MCMV) also induces CD46 expression on
infected fibroblasts. This upregulation was mapped to a
CMV responsive element within the CD46 promoter [6].
Mice typically express the complement regulator CRRY
instead of CD46 [7]. However, MCMV infected cells resist
complement lysis and CD46 expression is associated with
this decrease [6]. The viral proteins that interfere with this
specific, antibody-mediated complement activity during
MCMV infection have not been identified.
Fc Receptor Homologues
Clinical evidence supports a role for antibodies in limiting
cytomegalovirus infection [8] and modulation of anti-
body-mediated immunity would be beneficial for CMV
survival. CMV infected cells can bind immunoglobulins
in serum of seronegative individuals [9-12]. This phe-
nomenon was linked to the expression of Fc binding pro-
teins (FcBPs) on the surface of infected cells that are
specific for IgG but not other isotypes [13-15]. Both
MCMV and HCMV encode FcBPs. MCMV encodes one
FcBP, fcr-1 or m138. Although, m138 has no homology to
the HCMV Fcγ BP it has conserved structural features with
cellular Fcγ receptors (FcγRs) and the viral FcγR of HSV
(gE-gI) [16]. Normally the FcRs from the host interact
with the Fc region of Igs and mediate a number of effector
functions including phagocytosis, release of inflamma-
tory cytokines, and natural killer (NK) cell-mediated anti-
body dependent cellular cytotoxicity (ADCC)[17]. It has
been speculated that the Fc region of anti-CMV antibodies
bind the viral FcγR instead of host FcγRs and block antivi-
ral activities. m138 is important for MCMV replication in
vivo. However, both wild-type and B cell deficient mice
infected with a Δm138 MCMV mutant had lower viral tit-
ers in several organs compared to mice infected with wild-
type MCMV. Thus impaired growth of MCMV is not due
to an enhanced humoral immune response in the absence
of m138 (i.e. similar titers were found in the presence or
absence of humoral responses) [18,19]. Interestingly,
m138 downregulates expression of H60 and MULT-1, two
ligands of the activating NK receptor, NKG2D. The impor-
tance of this downregulation in vivo was demonstrated
when the Δm138 MCMV was found at two logs reduced
titer compared to wt MCMV. Both replicated equivalently
in NK cell depleted mice. The downregulation of MULT-1,
but not H60, is due to defective cellular trafficking that
results in degradation of the protein [20]. m138 also
decreases cell surface trafficking of the costimulatory mol-
ecule B7-1 on dendritic cells (DCs), interfering with the
ability of these cells to activate antigen specific T cells [21].
Thus the MCMV FcγR should broadly affect both NK cell
recognition and perhaps presentation to the adaptive
immune response, although in a manner different from
HSV-1 gE-gI.
Two HCMV FcγRs have been identified, gp34 and gp68,
which are encoded by the genes TRL11/IRL11 and UL119-
UL118, respectively [22,23]. Although the function of the
HCMV-encoded FcγRs has not been determined, initially
it was assumed they would function like the viral FcγR
from HSV-1 (gE-gI), which protects infected cells from
ADCC and complement activation [24,25]. Recently it
was shown that gp68 binds the same IgG domain and
with the same stoichiometry as HSV-1 gE-gI. However, the
two proteins have different pH requirements for binding
which may relate to different mechanisms following IgG
engagement, although this possibility requires additional
study [26].
Interferon-Mediated Immunity
While interferons (IFNs) are induced early during CMV
infection [27-32], CMVs encode a number of proteins that
mitigate the effects of IFN activation [33-35]. The type I
interferons IFNα and IFNβ are part of the innate immune
response to viral infections [36]. The binding of IFNα and
IFNβ to the IFN receptor induces Jak/Stat signalling lead-
ing to the rapid upregulation of interferon-stimulated
genes (ISGs), such as MHC class I molecules and various
cytokines [37]. Two HCMV immediate early gene prod-
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ucts, 72 kDa immediate early 1 (IE1) protein (IE1-p72)
and IE2 protein (IE86), interfere with IFN signalling. IE1-
p72 binds STAT2 inhibiting the ISG transcriptional activa-
tor, ISGF3, from binding to the ISG promoter [38,39].
IE86 blocks binding of the transcription factor NFκB to
the IFNβ promoter and leads to the downregulation of
IFNβ expression in HCMV infected fibroblasts [40,41].
The HCMV tegument protein pp65 (UL83) has been
implicated in blocking interferon activity early during
infection prior to transcription of the immediate early
gene products [30]. Microarray analysis using wt HCMV
and a UL83 deletion mutant revealed pp65 downregulates
numerous ISGs although the mechanism for this is
unclear [42]. Conflicting reports have attributed this
decrease to interference with either NFκB activity or
another transcriptional regulator, IRF-3, although both
authors suggest a pp65-mediated defect in nuclear locali-
zation of the transcription factors likely contributes to the
decreased activity [42,43]. However, a UL83 mutant virus
like that used in these previous studies was also shown to
have decreased IE86 expression. In contrast, cells infected
with an HCMV mutant in which stop codons were used to
disrupt pp65 expression, preserving IE86 expression,
showed no difference in IFN expression compared to wt
HCMV [44]. This suggests IE86 activity is crucial in miti-
gating IFN-mediated events following infection. Never-
theless, the conservation of UL83 within CMV genomes
and the attenuation of an MCMV lacking expression of the
murine pp65 homolog [45] points to the importance of
pp65 for CMV survival in vivo.
The MCMV encoded protein, M27, interferes with both
type I and type II (IFNγ) interferon activity by downregu-
lating the signalling molecule, STAT2 [46,47]. M27
decreases transcription of constituents of the immunopro-
teasome [48]. This IFNγ inducible proteasome enhances
MHC class I processing of peptides for presentation.
Therefore, M27 may not only protect MCMV from the
direct antiviral effects of interferon induction but also
interfere with the presentation of viral peptides to CD8+ T
cells, a common theme to be discussed below.
MCMV and HCMV also encode proteins that interact with
interferon induced gene products. The MCMV gene prod-
ucts m142 and m143 decrease activation of protein kinase
R (PKR) [49], an enzyme that blocks protein synthesis in
infected cells leading to impaired viral replication. PKR is
activated via dsRNA, which is produced during transcrip-
tion of complementary strands of the CMV genome. Both
m142 and m143 have dsRNA binding domains and may
interfere with the binding of PKR with dsRNA, preventing
its activation [50]. The HCMV encoded proteins TRS1 and
IRS1 are capable of binding dsRNA and can substitute for
the vaccinia virus (VV) RNA binding protein [51,52].
However, the role of these proteins in the context of
HMCV infection has not been evaluated [53].
Natural Killer Cells
Natural killer (NK) cells are cytotoxic cells of the innate
immune response that play an important role in eliminat-
ing virus-infected cells early during infection. Signalling
induced via activating receptors in absence of inhibitory
receptor signalling regulates the cytotoxic activity of NK
cells. Inhibitory receptors recognize specific MHC class I
alleles whereas a number of ligands can bind activating
receptors to trigger NK cell mediated killing. NK cells are
important for controlling CMV infections both in mice
and humans [54]. Therefore, it is not surprising the CMVs
encode numerous proteins that interfere with NK cell
activity [55].
Some HCMV encoded proteins alter expression of NK cell
receptor ligands. The UL16 encoded glycoprotein,
gpUL16, binds a number of ligands of the NK cell activat-
ing receptor, NKG2D. gpUL16 binds members of the
UL16-binding protein (ULBP) and MIC family of pro-
teins, which are stress induced NK ligands [56]. In partic-
ular, gpUL16 binds to ULBPs 1 and 2 [57,58] and MICB
[59]. gpUL16 downregulates these proteins, retaining
them intracellularly in the ER or Golgi network [60-62].
The interaction of gpUL16 with these ligands blocks NK
cell activation in vitro [56,57,63,64] and may represent a
way for HCMV to inhibit NK cell activation due to repli-
cation-induced cell stress.
Like gpUL16, the recently identified HCMV microRNA
(miRNA), miR-UL112, also decreases expression of the
NK ligand, MICB. miRNAs bind to 3' UTRs and prevent
their translation. The miR-UL112 mediated decrease in
MICB helps protect HCMV-infected cells from NK cell rec-
ognition and killing [65] and suggests that control of
MICB expression and avoidance of NK recognition is
important to the HCMV life cycle. As the field of CMV
miRNA's begins to expand, an understanding of the role
that miRNAs play in immune manipulation will also
expand.
MCMV also encodes three proteins that downregulate lig-
ands of the NK cell activating receptor, NKG2D. The m145
encoded protein decreases expression of MULT-1 [66], the
m155 encoded glycoprotein (m155) downregulates H60
[67], and the m152 encoded glycoprotein (gp40) down-
regulates proteins of the RAE-1 family [68-70]. MCMV
mutants lacking any one of these genes are attenuated in
vivo and NK cell depletion restores MCMV growth. These
results support a role for these proteins in inhibiting NK
cell mediated clearance [66,69,71,72]. Although the exact
mechanism of action is not known for these proteins,
both m155 and gp40 act at a post-transcriptional step and
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likely interfere with trafficking of NK ligands to the cell
membrane [67,69,72].
MCMV encodes two homologues of MHC class I mole-
cules, although neither has similarity to the HCMV
homolog, UL18 [73,74]. The MCMV gene m157 has low
sequence homology to MHC class I molecules but struc-
tural analysis shows it has MHC-like folds [75]. m157 is
expressed on infected cells and is tethered to the mem-
brane with a glycosylphosphatidylinositol (GPI) anchor
[76,77]. m157 binds to Ly49H, an activating receptor of
the Ly49 family of NK receptors [75,78]. Interestingly, the
m157-Ly49H interaction activates NK cells in vitro induc-
ing NK cell cytotoxicity and cytokine and chemokine
expression [79,80]. In the structural paper exploring
m157/Ly49H interactions, Adams et al showed that m157
activation of Ly49H is sufficient to override MHC I/NK
cell inhibition [81]. In vivo, MCMV mutants lacking m157
are more virulent in mice due to decreased NK cell activity
[82]. Furthermore, MCMV replicates to higher titers in
mouse strains that lack expression of Ly49H receptors
[83,84], demonstrating that Ly49H activation is impor-
tant for immune protection against MCMV. Although
Ly49H protects against MCMV in laboratory mice, MCMV
isolates from wild mice have m157 variants that fail to
activate NK cells, thus providing evidence of evasion of
NK recognition [85]. Mutations in m157 were also shown
to accumulate following multiple passages of MCMV in
mice indicating selection pressure for m157 variants that
fail to activate NK cells. Furthermore, m157 also binds the
inhibitory NK receptor, Ly49I, of some susceptible mice
strains such as 129/J [75]. This has led to the speculation
that CMVs evolved m157 to interact with NK inhibitory
receptors but in some strains of mice this immune manip-
ulation "backfires" and causes NK cell activation. These
data suggest that m157 activation of NK may occur less
frequently in natural infection of mice in the wild.
m144 is another MCMV encoded MHC class I homolog
[74,86]. m144 is expressed on the cell surface despite its
inability to bind endogenous peptides like other MHC
homologues [87]. m144 can inhibit NK cell cytolysis in
vitro [88], suggesting it serves as a decoy receptor to inhibit
NK cell activation. Consistent with this idea, MCMV
mutants without m144 expression grow poorly in mice
due to enhanced NK cell activation [89]. While a flexible
region within m144 that could potentially interact with
host receptors has been identified [90], m144 has not
been shown to bind any cellular receptors and its mecha-
nism of function remains unknown [88]. A rat CMV
(RCMV) homolog of m144, r144, has also been identified
[91]. Wild type RCMV shows enhanced replication in the
salivary gland and spleen of neonatal rats when compared
to an r144 deletion mutant [92]. However, what affect this
protein has on NK cell activity is not currently known.
HCMV encodes several proteins that interact with and
alter NK cell responses. One of the earliest identified pro-
teins, gpUL18, is encoded by the gene UL18 and is a MHC
class I homologue [93,94]. gpUL18 binds the β2-
microglobulin (β2m) and unlike the MHC homologue of
MCMV, m144, gpUL18 also binds endogenous peptide
[95,96]. gpUL18 binds the NK cell inhibitory receptor
LIR-1 with higher affinity than host MHC class I mole-
cules [97-100]. However, the function of gpUL18 has not
been clearly defined. gpUL18 expression both inhibits
and activates NK cells in vitro [101-106]. For instance,
gpUL18 activates NK cells from LIR-1- mice implicating a
complex mechanism for NK cell modulation. Further-
more, clinical isolates of HCMV express gpUL18 variants
with different LIR-1 binding affinities [107,108] that may
have differential functions. HCMV gpUL18-deletion
mutants have shown both gpUL18 dependent and inde-
pendent effects on NK cell activity in different cellular sys-
tems [101,109]. In addition to its effect on NK cells,
gpUL18 was recently shown to inhibit dendritic cell mat-
uration and migration. While dendritic cells express LIR-
1, whether this receptor mediates the effect of gpUL18 on
dendritic cell activity was not determined [110]. Impor-
tantly, the HCMV encoded proteins that downregulate
host MHC class I molecules do not interfere with the
expression of gpUL18, which provides "protection" from
NK cell lysis that occurs when MHC class I is downregu-
lated [111,112]. Collectively, current data suggests
gpUL18 may impact the function of several cell types in
vivo that may partially relate to its ability to bind and acti-
vate LIR-1 [113].
Recently, it was found that the UL142 gene encodes a sec-
ond HCMV MHC class I homologue [114]. Cells express-
ing gpUL142 are protected from NK cell lysis. However,
this effect was not evaluated in the context of HCMV infec-
tion [115]. While the mechanism of this effect has yet to
be determined, gpUL142 was shown to downregulate
MICA, a ligand for the activating NK cell receptor, NKG2D
[116].
Interestingly, HCMV increases expression of the non-clas-
sical MHC class I molecule, HLA-E, while downregulating
expression of many other MHC class I alleles [117]. This
upregulation is due to the expression of UL40, a HCMV
encoded protein that contains a peptide sequence identi-
cal to the HLA-E leader peptide [118-120]. Therefore,
UL40 increases expression of HLA-E independent of TAP
mediated peptide processing, which the HCMV encoded
protein, gpUS6, inhibits during infection [121]. HLA-E is
a ligand for the inhibitory receptor CD94/NKG2A and the
UL40 induced upregulation of HLA-E would be expected
to protect HCMV infected cells from NK cell lysis. How-
ever, conflicting reports have found UL40 inhibited or
had no effect on NK cell lysis of HCMV infected cells
Virology Journal 2009, 6:4 http://www.virologyj.com/content/6/1/4
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[117,122]. Additionally, the HLA-E restricted NK-CTLs
recognize the UL40 peptide and kill virally infected cells
[123,124]. Thus, whether UL40 protects HCMV infected
cells or targets them for destruction requires further eval-
uation.
The tegument protein, pp65, also interferes with NK cell
function by binding the activating receptor NKp30. pp65
mediates the dissociation of CD3ξ, a signal transducing
polypeptide, from NK cells impairing their activation
[125]. Since pp65 is not secreted or expressed on infected
cells, it is currently unclear how this protein mediates its
effects.
Finally, the protein product of UL141, gp141, decreases
the expression of CD155, a ligand for NK cell activating
receptors by inhibiting CD155 transport to the cell surface
[126]. This downregulation inhibits NK cell activity in
vitro but further information regarding its function and
impact in vivo remain to be answered.
Cytokine Homologues
Interleukin-10 (IL-10) is an immunosuppressive cytokine
that downregulates inflammatory cytokine synthesis and
interferes with antigen presentation by decreasing expres-
sion of MHC class II on antigen presenting cells [127].
Members of the poxvirus and herpesvirus families, includ-
ing HCMV, encode IL-10 homologues [128]. In contrast
to other viral IL-10 homologues, such as those encoded by
EBV and orf virus, a poxvirus, both of which have high
amino acid similarity (80%) to their host IL-10. The
HCMV IL-10 protein, cmvIL-10, has only limited homol-
ogy (27%) to human IL-10 (hIL-10) [129]. cmvIL-10
binds the IL-10 receptor, hIL-10R, albeit with lower affin-
ity than hIL-10 [129,130]. Nevertheless, it retains the
capacity to induce a strong anti-inflammatory response.
cmvIL-10 downregulates expression of IFNγ and TNFα in
peripheral blood mononuclear cells (PBMCs) and
decreases expression of both MHC class I and II on PBMCs
and DCs [130-133]. DCs exposed to cmvIL-10 ineffi-
ciently stimulated T cell proliferation [132] supporting its
role in immune suppression. Furthermore, cmvIL-10
inhibits cytokine production due to the activation of the
phosphotidylinositol 3-kinase pathway [134]. Interest-
ingly, cmvIL-10 was recently shown to stimulate B cell
proliferation but the impact of this on the immune
response to CMV is unclear [135]. cmvIL-10 alters the
function of non-leukocyte populations as well. By inter-
fering with placental cytotrophoblast invasion, cmvIL-10
could affect placental development, which contributes to
the sequelae observed following congenital CMV infec-
tions [136].
An alternatively spliced version of cmvIL-10 was origi-
nally identified during latent HCMV infection and termed
latency associated cmvIL-10 (LacmvIL-10) [137]. How-
ever, this transcript is also expressed during productive
infection [138]. LacmvIL-10 fails to induce signalling
pathways associated with IL-10R activation, which
implies LacmvIL-10 may not bind to IL-10R or, at least,
differentially activates this receptor. LacmvIL-10 also
decreases MHC class II expression on granulocyte-macro-
phage progenitors (GM-Ps) and monocytes, both sites of
CMV latency, possibly limiting clearance of latently
infected cells [139].
A number of primate CMVs encode proteins similar to IL-
10 [140] but only the function of the rhesus CMV
(RhCMV) homologue has been evaluated to date. Rhcm-
vIL-10 downregulates cytokine expression in PBMCs and
MHC class II molecule expression in monocytes [130].
Therefore, the function of human cmvIL-10 is conserved
in RhCMV. Interestingly, chimpanzee cytomegalovirus
(CCMV) and MCMV do not encode IL-10 homologues
[140]. MCMV infection induces cellular IL-10 expression
providing a mechanism for immune interference in the
absence of a virally encoded IL-10 protein [141,142].
Therefore, IL-10 immune suppression, whether cellular or
viral in origin, likely creates an environment that supports
efficient viral replication in the host.
Cytokine Receptor Homologues
The HCMV gene, UL144, encodes a protein with limited
homology to the herpes simplex virus entry mediator
(HVEM), a member of the tumour necrosis factor receptor
(TNFR) superfamily [143]. UL144 is the only TNFR
homolog identified in herpesviruses. The UL144 protein
does not bind any known TNF ligands [143-145]. UL144
binds to a member of the Ig superfamily, B and T lym-
phocyte attenuator (BTLA) [146], also a ligand of HVEM
[147]. Binding of UL144 to BTLA blocks T cell prolifera-
tion and could impair lymphocyte responses to HCMV
[146]. UL144 activates TNFR-activated factor (TRAF6)
leading to NFκB activation and upregulation of the chem-
okine CCL22 [145,148]. CCL22 is a chemoattractant of
Th2 and regulatory T cells. Activation and attraction of
these cells may help HMCV evade T cell-mediated antivi-
ral activity. UL144 is located in the UL/b' region of
HCMV, a portion of the genome thought to encode poten-
tial virulence factors. Different UL144 genotypes have
been identified in clinical isolates. However, all but one
report has found no association between the different
genotypes and CMV disease [144,149-155]. Although
there is much speculation on the role that UL144 plays in
immune modulation, its role in CMV pathogenesis and
survival is still unclear.
Viral Chemokine Homologues
Many CMVs also encode chemokine homologues. Chem-
okines are small, chemotactic cytokines that are important
Virology Journal 2009, 6:4 http://www.virologyj.com/content/6/1/4
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for leukocyte trafficking and activation. The best charac-
terized of the CMV chemokines is the CC chemokine
homolog of MCMV. Originally identified as the m131
gene product, MCK1, transcriptional analysis during
MCMV infection determined that a spliced product of
m131 and m129, referred to as MCK2 was the only tran-
script encoded from this locus. The CC chemokine
domain is confined to the MCK1 coding region and is
connected to a long carboxyl-terminal domain (199
amino acids) with no known homology to other proteins.
This makes MCK2 considerably longer than other chem-
okines [156,157]. In contrast to UL146 (see below), the
DNA sequence of MCK2 is highly conserved in isolates
from wild mice [158].
Initial studies in vitro showed MCK1 induced higher levels
of Ca2+ mobilization in peritoneal exudates cells from
MCMV infected mice than cells from uninfected mice.
This demonstrated that MCK1 could activate cells
recruited to the site of MCMV infection [159]. The spliced
product, MCK2, is important for viral spread within the
host. When a recombinant MCMV with mutations in the
m131 gene (generated either via point mutations or inser-
tions) was inoculated into mice, these recombinants
showed a defect in dissemination to the salivary gland.
Mice infected with these mutants developed less inflam-
mation at the site of inoculation, reduced secondary
viremia, as well as lower viral titers in the salivary glands,
a site of dissemination following secondary viremia
[160,161]. This was the first direct evidence that a CMV
encoded chemokine is important for the dissemination of
the virus in its host. Additional work identified the MCK2-
recruited cell type as a late myeloid progenitor, consistent
with reports that CMV infects and can remain latent in
cells of the myelomonocytic lineage [162].
Rat CMV (RCMV) encodes a CC chemokine with similar-
ity to both m131 and m129, having N-terminal chemok-
ine homology and a long carboxyl-terminus like MCK2
[163]. Rats infected with RCMV deletion mutants lacking
pr131 expression, the product of the r131 locus, had
reduced viral loads in the spleen and salivary glands.
Additionally these mice had reduced swelling and macro-
phage infiltration at the site of virus inoculation [164].
Therefore, pr131 appears to be a functional homolog of
MCK2.
Guinea pig CMV (GPCMV) contains a gene with homol-
ogy to CC chemokines, though it lacks positional or
sequence similarity to the m131/m129 genes of MCMV.
GPCMV-MIP is most similar to the cellular chemokines,
CCL3/CCL4 (MIP-1α/β) and CCL14 (HCC-1). GPCMV-
MIP induced Ca2+ flux and migration of cells expressing
hCCR-1 but did not elicit a response from cells expressing
other CC receptors [165]. CCL14 is known to increase the
proliferation of monocyte progenitors, therefore GPCMV-
MIP may enhance the proliferation and/or recruitment of
permissive cells consistent with the role of MCK2 [166].
HCMV encodes two ORFs with homology to CXC chem-
okines, UL146 and UL147 [167]. While no functional
data is available for the protein product of UL147, vCXCL-
2 (also called pUL147 and vCXC-2), analysis of the pro-
tein product of UL146, vCXCL-1 (also denoted pUL146
and vCXC-1), demonstrated its capacity as a functional
chemokine. vCXCL-1 was shown to bind exclusively to
hCXCR2 with an affinity similar to that of the host chem-
okine, CXCL8. Additionally, vCXCL-1 was able to induce
chemotaxis and intracellular calcium release in human
neutrophils, again to levels comparable to host chemok-
ines [168]. A mutant HCMV virus with a deletion of
UL146-UL147 was unable to infect neutrophils but
retained its ability to infect other cells providing addi-
tional evidence these proteins facilitate an interaction of
HCMV with neutrophils [169].
Chimpanzee CMV (CCMV) encodes homologues of
UL146 and UL147 as well as the related gene UL146a.
However, only the product of UL146 (vCXCL-1CCMV) has
been evaluated thus far. vCXCL-1CCMV induces chemotaxis
and calcium release in human neutrophils. Additionally,
it was shown to increase expression of adhesion mole-
cules on the surface of neutrophils and reduce apoptosis
in these cells [170]. Taken together, the function of the
HCMV and CCMV vCXCL-1s in vitro suggest the potential
for these viral chemokines to alter the response of neu-
trophils in the course of CMV infection.
Due to the strict species specificity of CMVs, in vivo char-
acterization of UL146 and UL147 has been limited to
sequence analysis of clinical HCMV isolates. UL146 is
highly variable, differing as much as 60% among isolates
at the amino acid level [152]. It was postulated that this
variability might correlate with the severity of CMV dis-
ease however no clear relationship has been identified
[151,171-173]. It was recently suggested the variability of
UL146 may have arisen in early human populations and
likely does not contribute to the pathogenesis of congeni-
tal infection [173]. Our lab is currently working to identify
whether the vCXCL-1 isolates from different clinical
strains induce functional differences in neutrophils.
HCMV also encodes genes with limited homology to CC
chemokines. UL128 and UL130 both have signal
sequences and conserved cysteine motifs similar to CC
chemokines [174], but it is yet to be determined whether
these proteins actually function as chemokines. Interest-
ingly, the UL128-131 locus was found to be necessary for
endothelial cell and leukocyte tropism based on the ina-
bility of HCMV UL128-131 deletion mutants to infect
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these cell types [169]. This likely explains the loss of
endothelial cell tropism in lab-adapted strains of HCMV,
a number of which were shown to have deletions or muta-
tions in at least one gene from this region [174]. The
UL128-131 proteins have recently been shown to interact
with gH/gL complexes that mediate entry of CMV into
endothelial and epithelial cells, in contrast to the gH/gL
complexes that mediate virus entry into fibroblasts
[175,176].
Chemokine Receptor Homologues
In addition to viral chemokine homologues, CMVs
encode proteins with homology to chemokine receptors
[177,178]. Chemokine receptors are members of the G-
protein coupled receptor (GPCR) family [179]. The four
chemokine receptor homologues encoded by the cytome-
galoviruses have homology to the CC chemokine receptor
family. Two genes, UL33 and UL78, are conserved among
all sequenced CMVs, while primate CMVs encode two
additional GPCRs, US27 and US28 [180].
The HCMV US28 encoded protein (pUS28) is the best
characterized of the GPCR homologues. US28 has the
highest sequence homology to the cellular receptor,
CCR1, and binds a number of CC chemokines including
CCL5 (RANTES), CCL2 (MCP-1), CCL3 (MIP-1α), and
CCL4 (MIP-1β) [181,182]. Interestingly, pUS28 binds
with highest affinity to the CX3C chemokine, CX3CL1
(fractalkine) [183]. Upon binding, pUS28 induces chem-
okine internalization, removing chemokines from the
extracellular environment [184-186]. Consistent with this
role, pUS28 inhibits monocyte migration in vitro and
media from US28 expressing, CMV-infected monolayers
deplete CCL5 and CCL2 from the media [187]. Constitu-
tive endocytosis and recycling of pUS28 contributes to
chemokine internalization however chemokine binding
is not sufficient to induce constitutive endocytosis of
pUS28 [188]. By acting as a "chemokine sink", pUS28
could alter or inhibit chemokine-dependent immune
responses. The related chemokine homolog, pUS27, also
shows some ability to internalize chemokines [185,189],
perhaps illustrating a conservation of function between
the viral GPCRs.
pUS28 elicits ligand-dependent signalling, triggering cal-
cium mobilization upon CCL5, CCL2, CCL3 and CCL7
binding. pUS28 utilizes the G proteins Gαi and Gα16 to
mediate calcium mobilization upon binding of CCL5 or
CCL7 [181,190,191]. Interestingly, Gα16 expression is
restricted to hematopoietic cells [192]. HCMV has a tro-
pism for this cell lineage where pUS28 may alter Gα16 sig-
nalling to benefit CMV's life cycle. pUS28 also induces
agonist-dependent migration of smooth muscle cells
(SMCs). Migration of SMCs in response to pUS28 requires
the protein tyrosine kinase (PTK) pathway, indicating
pUS28 activates a number of cellular pathways in vitro
[193,194]. As with many CMV proteins, the effects of
pUS28 vary depending on the system and cell types ana-
lyzed.
Like the Kaposi's sarcoma-associated herpesvirus (KSHV)
GPCR homolog, ORF74 [195], pUS28 can constitutively
activate several signalling pathways, including phosphol-
ipase C (PLC), NFκB, NFAT, and cAMP-responsive ele-
ment (CRE)-dependent pathways [188,191,195-198]. CC
chemokines do not enhance signalling, although CX3CL1
acts as a partial inverse agonist, decreasing the levels of
pUS28 constitutive activity [191,196]. The constitutive
endocytosis of pUS28 occurs independently of its consti-
tutive signalling and different domains of pUS28 control
these two phenomena [188]. pUS28, like KSHV ORF74,
can induce transformation of NIH3T3 cells and promote
tumour formation in nude mice. Mice inoculated with
cells expressing a mutated pUS28 that lacks constitutive
activity show attenuated tumour formation demonstrat-
ing the importance of constitutive signalling in pUS28-
mediated tumour formation [199].
Despite extensive research on the function of pUS28, its
role in CMV pathogenesis in vivo is still unknown. pUS28
sequesters host chemokines in order to alter the immune
response or activates signalling pathways that contribute
to viral replication or spread. pUS28-induced SMC migra-
tion may play a role in the accelerated vascular disease
associated with HCMV [200,201]. Although HCMV
nucleic acids have been isolated from certain cancers
[202,203], whether HCMV is causal in these cancers
remains to be established. Perhaps pUS28 may contribute
to tumour formation in these individuals.
The UL33 gene is conserved in all β herpesviruses, includ-
ing HCMV (UL33), RCMV (R33), and MCMV (M33).
While no ligands have been identified for either pUL33 or
pR33, pM33 is activated by CCL5 [204]. All three viral
proteins show constitutive activity, although they differ-
entially activate specific signalling pathways [196,205-
207]. While not essential for viral replication in vitro, both
pR33 and pM33 are important for replication of CMV in
the salivary gland [208-210]. In MCMV, this defect was
linked to the constitutive activity of pM33 [211] and illus-
trates the importance of constitutive signalling in vivo.
Like pUS28, pM33 and pR33 induce SMC migration
[204,212]. Taken together, this suggests GPCRs of the
UL33 family alter cellular trafficking during CMV infec-
tion, which may contribute to viral pathogenesis.
The UL78 gene family encoded proteins have only limited
homology to known chemokine receptors [180]. Never-
theless, this gene is conserved in all β herpesviruses sug-
gesting they have some role in the herpesviruses life cycle.
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The UL78 proteins of MCMV and RCMV, pM78 and pR78,
respectively, are important for viral replication in vitro and
in vivo [213-215]. The HCMV homolog, pUL78, is not
required for replication of HCMV in vitro [216] thus
MCMV and RCMV may be more dependent on its func-
tion for viral replication. Although, members of the UL78
family are clearly important for viral replication for some
CMVs, data regarding their specific function as GPCRs is
not currently available.
Viral Chemokine Binding Proteins
Chemokine binding proteins (CBPs) are virally encoded
secreted proteins that competitively bind chemokines and
interfere with their interactions with cellular receptors.
Unlike viral chemokine and chemokine receptor homo-
logues, which were likely acquired from the host, CBPs
generally show no homology to known proteins and
homology of these proteins across viruses is not conserved
[217]. Until recently, no CMV species was known to
encode a CBP. However, a HCMV encoded protein, p21.5,
has been identified with chemokine binding properties.
mRNA transcripts of the gene UL21.5 are packaged in the
HCMV virion and thus may function soon after viral entry
into the cell. Although many CBPs interact with multiple
chemokines [218], p21.5 is unusual in that it selectively
binds CCL5 (RANTES) in vitro blocking the interaction of
the chemokine with its cellular receptors [219]. No data is
available which evaluates the ability of p21.5 to interfere
with CCL5 function in vivo and its effect on viral survival.
Apoptosis
Apoptosis is a mechanism for programmed cell death that
plays an important role in the elimination of cells during
development and virally infected cells as part of the host's
innate immunity [220,221]. Many viruses including
CMVs have strategies to prevent apoptosis [222,223].
HCMV encodes two proteins in particular that directly
interfere with the apoptosis pathway. The HCMV UL36
gene encodes a viral inhibitor of caspase-8 induced apop-
tosis (vICA) and exon 1 of UL37 encodes the viral mito-
chondrial inhibitor of apoptosis (vMIA) [224].
vMIA protects cells from intrinsic apoptosis induced fol-
lowing damage to the mitochondrial membrane [225-
227]. vMIA only blocks apoptosis mediated through the
death receptor, Fas, in cells in which apoptosis proceeds
through a mitochondrial-dependent step [228]. vMIA has
not been identified in virion particles and inhibits apop-
tosis at later times compared to vICA [225,229]. vMIA
localizes to the mitochondria [230-232] and this localiza-
tion is needed for vMIA to induce structural changes and
inhibit mitochondrial release of cytochrome c, blocking
downstream events in the apoptosis pathway [227,233].
vMIA also induces the release of calcium from the ER
which may play a role in the inhibition of apoptosis
[234].
vMIA was initially shown to interact with adenine nucle-
otide translocator (ANT), a regulator of mitochondrial
membrane permeability [227,235]. However, this interac-
tion does not correlate with vMIA function and is likely
non-specific [235]. vMIA also binds the proapoptotic pro-
tein, Bax, inducing aggregation of Bax molecules at the
mitochondrial membrane preventing membrane permea-
bilization [236,237]. The screening of proteins that inter-
act with the antiapoptotic domain of vMIA identified the
protein, Growth Arrest and DNA Damage 45
(GADD45α). GADD45α enhances vMIA-induced apopto-
sis possibly protecting it from proteasomal degradation
[238]. Interestingly, vMIA was also recently shown to
interfere with caspase-independent cell death by blocking
the activity of the serine protease, HtrA2/Omi [239].
Sequence homologues of vMIA have only been found in
primate CMVs [240]. However, a recently identified posi-
tional homologue of vMIA in MCMV, m38.5, was shown
to interact with Bax and inhibit apoptosis [226,241,242].
Therefore, vMIA functional homologues may exist in
other cytomegaloviruses.
In contrast to vMIA, vICA protects cells in vitro from
extrinsic apoptosis mediated through ligation of the death
receptors, Fas and TNFR-1 [228]. vICA is a virion constit-
uent [243] that inhibits caspase-8 activation [228]. Pro-
caspase-8 is prevented from interacting with the adapter
protein, Fas-associated death domain (FADD) and inhib-
its the processing of procaspase-8 to its active form [244].
Therefore, vICA is functionally similar, although mecha-
nistically distinct from, cellular and viral FLICE inhibitory
proteins (FLIPS), which also interfere with caspase-8 acti-
vation [245].
vICA is dispensable for replication and some HCMV lab
strains have inactivating mutations in the UL36 gene
[228,243,246]. Nevertheless, vICA homologues are con-
served in the genomes of all sequenced β-herpesviruses
except for guinea pig CMV (GPCMV) where no positional
homologues has been identified [247]. The vICA homo-
logues of RhCMV and MCMV, Rh36 and M36, respec-
tively, also have antiapoptotic activities when transiently
expressed in vitro [240,248]. Recently, it was shown that a
M36 deletion mutant was attenuated in the lungs and sal-
ivary glands of mice but could be rescued by expression of
a dominant-negative variant of FADD [249]. This pro-
vides important evidence for the functional significance of
this protein in vivo.
The MCMV M45 encoded protein has sequence, although
not functional, homology to a cellular ribonucleotide
reductase [250,251]. Nevertheless, a M45 mutant virus is
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attenuated in SCID mice [251]. Recently M45 was shown
to suppress the cell death pathway in a manner unique to
viral proteins [252]. M45 interacts with the receptor-inter-
acting protein kinase I (RIPI) via a RIP homotypic interac-
tion motif (RHIM). By binding to RIPI, M45 protects
certain cell types from caspase-independent cell death fol-
lowing death receptor signalling [253,254]. This "alterna-
tive apoptosis" would likely be activated in HCMV
infected cells in which vICA inhibits caspase-8 activity
[255].
Adaptive Immune Response
T Cell Mediated Immunity
T cell mediated immune responses, particularly CD8+ T
cell dependent responses, are integral to the clearance of
cytomegalovirus infections [54]. Cytomegaloviruses, as
do many herpesviruses, impair T cell activation by inter-
fering with both MHC class I and II antigen processing
and presentation [256]. Although this has been shown in
vitro, Th or CTL responses are still generated during CMV
infection in vivo [257-260].
The US region of the HCMV genome encodes a number of
endoplasmic reticulum (ER) resident glycoproteins that
alter MHC class I expression [261]. The first of these pro-
teins to be expressed following HCMV infection is the US3
encoded immediate early protein, gpUS3, which likely
interferes with T cell recognition early during viral replica-
tion [262-264]. gpUS3 binds MHC class I molecules and
retains them in the ER, inhibiting antigen presentation to
CD8+ T cells [265-269]. The transmembrane domains of
gpUS3 are responsible for binding MHC class I [270,271].
However, luminal regions of gpUS3 are needed for reten-
tion of MHC class I in the ER [270-273]. Interestingly,
gpUS3 also binds tapasin and this interaction prevents
tapasin-mediated protein loading of MHC class I mole-
cules. Therefore, gpUS3 only retains MHC class I alleles
that are tapasin dependent [274]. An alternatively spiced
form of gpUS3 competitively binds tapasin and may rep-
resent a regulatory mechanism for gpUS3 activity [275].
In contrast to gpUS3, the binding of MHC class I mole-
cules to the US2 and US11 encoded HCMV proteins,
gpUS2 and gpUS11, leads to the rapid degradation of
MHC class I molecules [276-279]. Both proteins bind
MHC class I molecules resulting in their removal from the
ER to the cytosol where they undergo proteasome-
dependent degradation [266,276,277]. This process
requires a functional ubiquitination system although only
gpUS2 specifically depends on MHC class I ubiquitina-
tion for protein degradation [280-283]. In addition to the
ubiquitin system, gpUS2 and gpUS11 associate with other
cellular proteins that facilitate recognition and removal of
proteins via the endoplasmic reticulum associated protein
degradation (ERAD) pathway [284-287]. gpUS2 forms a
complex with the chaperones, calnexin, BiP, and calreticu-
lin to mediate MHC class I degradation [288]. In contrast,
gpUS11-dependent protein degradation requires Derlin-
1, a protein that plays a role in the removal of misfolded
proteins [289].
Why HCMV encodes two different proteins that target
MHC class I for degradation is unclear. gpUS2 and
gpUS11 differ in their specificities for MHC class I alleles
[290,291]. While they may overlap in function, they likely
mediate distinct effects on MHC class I expression
[292,293]. This difference in specificity is likely the result
of different binding requirements for gpUS2 and gpUS11.
The luminal portion of gpUS2 interacts with residues in
the α2/α3 region of the luminal domain of MHC class I
molecules [294-296]. Specifically, gpUS2-mediated deg-
radation requires the presence of an arginine at residue
181 of MHC class I molecules. However, this residue is
not sufficient for degradation of some MHC class I alleles
and other residues must be important for these molecules
[297]. The luminal region of gpUS11 is also important for
MHC class I binding, however, gpUS11 interacts with res-
idues in the α1/α2 domain of MHC class I molecules
[298,299].
The HCMV US6 gene, encodes another glycoprotein,
gpUS6, that downregulates MHC class I expression
[121,300,301]. Like the other US proteins that interfere
with MHC class I expression, gpUS6 mediates retention of
MHC class I via its luminal domain [302]. However, the
gpUS6 mechanism is unique in that it binds to TAP-1 and
TAP-2 heterodimers [303] in the transporter associated
with antigen processing (TAP) complex
[121,300,304,305]. Through its association with TAP,
gpUS6 prevents the binding of ATP to TAP [306] and sub-
sequent TAP peptide translocation [300,301]. gpUS6
expression is solely responsible for the inhibition of TAP
in HCMV infected cells [307] and downregulates all MHC
class I alleles tested [308]. In addition to impairing CD8+
T cell responses, this decrease in MHC class I expression
also makes infected cells susceptible to NK cell cytotoxic-
ity [308], which may explain why CMVs have evolved
mechanisms for preventing NK lysis (NK cell section).
Two additional HCMV encoded proteins, gpUS8 and
gpUS10, bind MHC class I molecules. However, neither
protein downregulates cell surface MHC class I expres-
sion, although gpUS10 slows MHC class I maturation and
egress from the ER. The function of these proteins in
HCMV infection is currently unknown [309,310].
Other cytomegaloviruses have homologues of some of the
HCMV US family members. CCMV encodes a gpUS6
homologue that binds TAP. However, this interaction
does not downregulate MHC class I expression in chim-
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panzee cells in vitro, making the function of this homo-
logue unclear [305]. In contrast, RhCMV encodes
homologues of gpUS2, gpUS3, gpUS6, and gpUS11 [311],
each of which functions similarly to its HCMV counter-
part [312]. A newly identified RhCMV protein, viral inhib-
itor of heavy chain expression (VIHCE), is encoded by the
rh178 gene, a gene unrelated to the US6 gene family.
VIHCE inhibits signal-peptide dependent MHC class I
heavy chain translation, a mechanism distinct from other
modulators of MHC class I expression [313]. Therefore,
RhCMV may be a valuable model system for analyzing the
function of these proteins during CMV infection in vivo.
MCMV encodes three proteins unrelated to those of
HCMV that interfere with MHC class I expression in
infected cells. m6, m152, and m4, encode gp48, gp40, and
gp34 respectively. Both gp40 and gp48 inhibit antigen
presentation to CD8+ T cells in vitro [314,315]. gp40 and
gp48 bind MHC class I molecules and retain them intrac-
ellularly [314-316], although each protein does so via dif-
ferent mechanisms. gp40 retains MHC class I molecules in
the ER-Golgi intermediate compartment (ERGIC)-cis
golgi network [314] whereas gp48 binds to MHC class I
molecules and targets them to lysosomes for degradation
[315]. Deletion of m152 restores MHC class I expression
in MCMV infected cells suggesting gp40 is the main regu-
lator of MHC class I downregulation [317,318]. However,
gp48 cooperates with gp40 to enhance MHC class I reten-
tion in vitro [319]. gp48 and gp40 also show different spe-
cificities for MHC class I alleles and thus are both required
for efficient MHC class I downregulation in certain cell
types [320,321]. Surprisingly, the presence of m152 does
not impact the CTL response in mice based on studies
using recombinant MCMVs. Therefore, the in vivo role of
m152 as well as m4 and m6 is not clear [322-324]. One
possible explanation for this lack of CTL alteration in vivo
is uninfected antigen presenting cells (APCs) cross-prim-
ing CD8+ T cells, which could circumvent function of
gp40 in mice [324]. If these proteins cannot prevent prim-
ing of CD8+ T cells, what is their function? There are a cou-
ple of possibilities. One is that the delay in CD8+ T cell
recognition is enough to allow the virus to establish a
foothold within the host and eventually establish latency.
Also without this initial CD8+ T cell recognition, immun-
opathology could be diminished allowing the host to sur-
vive and viral spread. Recently the Reddehase group has
shown that the presence of these immune modulating
proteins (gp40, and gp48) actually enhance priming of
CD8+ T cells [325]. How this benefits CMV survival in vivo
is hard to reconcile, but may represent the evolution of
mouse immune responses to counter these "immuneva-
sions." The Reddehase and Hill labs are both actively per-
suing answers to these questions and why CMVs would
have evolved mechanisms to enhance CTL priming.
The MCMV protein gp34 also associates with MHC class I
molecules [326,327]. In contrast to gp40 and gp48, gp34
decreases the intracellular retention of MHC class I mole-
cules [319,326]. However, this phenomenon is seen only
in the absence of m6 (gp48) suggesting gp48 expression
may antagonize the function of gp34 and provide a mech-
anism to regulate the extent of MHC class I expression in
infected cells [317,319].
HCMV can also interfere with the presentation of MHC
class II on antigen presenting cells such as macrophages
[328]. gpUS3, gpUS2, and pp65 mediate this effect.
gpUS3 binds and downregulates MHC class II, which sub-
sequently decreases antigen presentation to CD4+ T cells.
gpUS3 interferes with the sorting of MHC class II to lyso-
somes inhibiting peptide loading in these compartments
and subsequent MHC class II expression at the cell surface
[269]. gpUS2 also interferes with CD4+ T cell recognition
by downregulating MHC class II molecules. Similar to its
effect on MHC class I, gpUS2 binds the α chain of MHC
class II resulting in the proteasome-dependent degrada-
tion of MHC class II molecules in a number of different
cell types in vitro [269,329-331]. Lastly, the tegument pro-
tein, pp65, also downregulates MHC class II expression.
Yet another mechanism for MHC class II down regulation,
pp65 mediates MHC class II trafficking to lysosomes caus-
ing their destruction [332]. MCMV infection also down-
regulates MHC class II expression although the viral
proteins responsible for this are not currently identified
[141,333]. As observed with MHC class I downregulation,
CMVs have evolved multiple modes for achieving manip-
ulation of MHC class II host responses in order to achieve
evolutionary success.
Conclusion
Whether it is the destruction of important immune mole-
cules, a redirection of these proteins intracellularly, tran-
scriptional or translational control, alteration of signal
transduction cascades, or the production of novel interfer-
ing proteins, CMVs "push" and "pull" at the immune
response in such a way as to ensure their evolutionary suc-
cess. Based on the numerous viral proteins that respond to
the host's defence mechanisms, the relationship of CMVs
with their hosts is complex. In spite of the manipulation
of both the magnitude and quality of the innate and adap-
tive immune responses, the host still launches a robust
anti-CMV immune response but not before the virus
establishes latency within the host. Therefore CMV infec-
tion does not eliminate host immunity but modulates it
to allow survival of both the virus and the host, as both are
important to the life cycle of the virus. With its millions of
years of co evolution within us, we can use CMVs acquired
"knowledge" of the immune system to uncover novel
immune pathways. We can potentially exploit CMVs
potential vulnerabilities for developing CMV vaccines (i.e.
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ones that can not establish latency) or novel therapeutics
that could minimize CMV-induced damage in immune
compromised hosts.
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